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Abstract 1 
Higher blood pressure (BP), BP variability and leukoaraiosis are risk factors for early adverse 2 
events and poor functional outcome after ischaemic stroke, but prior studies differed on 3 
whether leukoaraiosis was associated with BP variability, including in ischaemic stroke.  4 
 5 
In the Third International Stroke Trial, BP was measured in the acute phase of ischaemic stroke 6 
immediately prior to randomization, and at 0.5, 1 hour and 24 hours after randomization. 7 
Masked neuroradiologists rated index infarct, leukoaraiosis and atrophy on CT using validated 8 
methods. We characterised BP variation by coefficient of variance (CV) and three other 9 
standard methods. We measured associations between BP, BP variability and leukoaraiosis 10 
using generalized estimating equations, adjusting for age, and a number of covariates related 11 
to treatment and stroke type/severity. 12 
 13 
Amongst 3017 patients, mean (±SD) systolic and diastolic BP decreased from 14 
155(±24)/82(±15)mmHg pre-randomization to 146(±23)/78(±14)mmHg 24 hours later 15 
(P<0.005). Mean within-subject CV was 0.09±0.05 for systolic and 0.11±0.06 for diastolic BP. 16 
Patients with most leukoaraiosis were older and had higher BP than those with least 17 
(P<0.0001). Although statistically significant in simple pairwise comparisons, no measures of 18 
BP variability were associated with leukoaraiosis when adjusting for confounding variables 19 
(P>0.05), e.g., age.  20 
 21 
Our results suggest that BP variability is not a potential mechanism to explain the association 22 
between leukoaraiosis and poor outcome after acute stroke. 23 
 24 
25 
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Introduction 1 
Higher blood pressure (BP) level and BP variability are risk factors for early adverse events 2 
and later poor functional outcome after stroke(1, 2). Higher long-term BP has consistently been 3 
associated cross-sectionally with a higher burden of leukoaraiosis, which is itself a major risk 4 
factor for stroke, dementia, and death(3-8); and independently predicts poor outcome after 5 
stroke(9). However, there are conflicting reports on the association between higher long-term 6 
BP variability and the burden of leukoaraiosis(6, 7, 10, 11) and short-term BP variability and 7 
leukoaraiosis(10, 12, 13). This discord among a relatively small number of studies, mostly with 8 
N<250 and only one with greater than 500 participants, is in contrast to the often studied and 9 
well characterized associations between higher absolute BP and more leukoaraiosis(14). 10 
 11 
The sample sizes in these studies were often relatively small (N<500)(10, 12, 13) and/or were 12 
in community-dwelling participants(6, 11), or during long-term follow-up after stroke(7), 13 
which might contribute to differing results. We found no previous investigations of the 14 
associations between pre-existing leukoaraiosis and variability in BP during the acute phase of 15 
stroke. Yet the acute phase of stroke is a time when BP is likely to be highly variable(15, 16). 16 
 17 
We previously studied the effect of BP variability(1) and of leukoaraiosis(9) on outcome after 18 
ischaemic stroke. Given the independent negative prognostic impacts that we found in these 19 
previous studies, we aimed to clarify the relationship between BP variability and leukoaraiosis 20 
in the acute phase of ischaemic stroke using data from a large randomized trial, the Third 21 
International Stroke Trial (IST-3)(9, 17-19). 22 
 23 
24 
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Methods 1 
Participants 2 
IST-3 was conducted with 3035 participants recruited from 156 centres in 12 countries(19). 3 
All participating centres had a national co-ordinator and local ethics approval. The trial, 4 
registered at ISRCTN.com, number ISRCTN25765518, was run according to the local 5 
procedures and law of each centre(18). All patients or an assigned patient 6 
relative/representative (where patients did not have capacity) gave informed consent. Full 7 
details of trial procedures, including imaging assessments, patient characteristics and the main 8 
trial results, have been published(9, 17-19).  9 
 10 
BP measurement 11 
BP was recorded by trained personnel for trial purposes at five time points: pre-randomization, 12 
start of treatment (or immediately after randomization for control patients), and at 30 minutes, 13 
60 minutes, and 24 hours after treatment. We recorded whether BP was treated prior to 14 
admission in the trial, within the first 24 hours, and/or between 24 hours and seven days after 15 
randomization. 16 
 17 
BP variability 18 
We assessed variability in BP via measures of systolic, diastolic, pulse, and mean arterial 19 
pressure taken pre-randomization, at the start of treatment, and 30 minutes, 60 minutes, and 24 20 
hours after treatment.  21 
 22 
We calculated mean arterial pressure (MAP) via equation 1: 23 
 24 
MAP=DBP+
SBP-DBP 
3
 
(1) 
 25 
According to previous studies(6, 7, 13), we used standard deviation, coefficient of variance 26 
(CV), average real variability, and successive variation to quantify variance in each measure 27 
of BP. 28 
4 
 
Average real variability (ARV) was computed for all four measures of BP via equation 2: 1 
 2 
ARV=
|BPstart-BPrand|+|BP30m-BPstart|+|BP60m-BP30m|+|BP24h-BP60m|
4
 
(2) 
 3 
 4 
Successive variability (SV) was computed for all four measures of BP via equation 3: 5 
 6 
SV=
(BPstart-BPrand)
2+(BP30m-BPstart)
2+(BP60m-BP30m)
2+(BP24h-BP60m)
2
4
 
(3) 
 7 
 8 
Pre-existing brain damage 9 
Leukoaraiosis, including anterior and posterior (each scored 0-2), burden and whole brain 10 
atrophy, were rated by trained neuroradiologists on computed tomography (CT) masked to all 11 
clinical details using previously validated procedures(9, 20, 21). Anterior and posterior 12 
leukoaraiosis scores were summed to compute a total leukoaraiosis score (on a continuum of 0 13 
to 4; with 4 being the greatest leukoaraiosis burden). Whole brain atrophy was scored for 14 
central and cortical structures as none, moderate, or severe, then dichotomised into a single 15 
variable as either absent (0) or present in one or both regions (1). 16 
 17 
Statistical analyses 18 
All statistical analyses were performed in the Statistical Analysis System (SAS) version 9.4 (© 19 
2002-2012 SAS Institute Inc.). We used longitudinal multiple regression (generalized 20 
estimating equations) to model absolute BP (separate models for systolic, diastolic, pulse, and 21 
mean arterial pressure) over time according to leukoaraiosis burden and adjusted for age, 22 
atrophy, NIHSS, stroke subtype, time to randomization, treatment allocation, and BP lowering 23 
treatment before the trial, during the first 24 hours, and between 24 hours and seven days. This 24 
analysis is summarised in equation 4: 25 
 26 
5 
 
BP=β_Time+β_Age+β_Leukoaraiosis+β_Atrophy+β_NIHSS+β_StrokeSubtype+ 
β_TimeRand+β_TreatmeentAlloc+β_BPlowPrior+β_BPlowDay1+ 
β_BPlowDay2-7+error 
(4) 
 1 
We also used generalized estimating equations to measure associations between leukoaraiosis 2 
and BP variability with the same adjustment variables. This analysis is summarised in equation 3 
5: 4 
 5 
Leukoaraiosis=β_DBPV+β_SBPV+β_PPV+β_MAPV+β_Age+β_NIHSS+β_Atrophy+ 
β_StrokeSubtype+β_TimeRand+β_TreatmeentAlloc+β_BPlowPrior+β_BPlowDay1+ 
β_BPlowDay2-7+error 
(5) 
 6 
We defined leukoaraiosis as the dependent variable in equation 5 as this allowed all measures 7 
of BP (systolic, diastolic, pulse, and mean) to be assessed in one model (rather than four 8 
separate models where each measure of variability was the dependent variable). We assessed 9 
collinearity using variance inflation factor and stepwise removal of potentially volatile 10 
variables. The generalized estimating equations used here are parametric (mean-based) and 11 
although leukoaraiosis often has highly skewed distributions, we found this to have a nominal 12 
effect on mean-based regression results(14). We used an exchangeable correlation matrix in 13 
our generalized estimating equations because repeated BP measures were correlated but not 14 
autoregressive. We assessed overfitting by comparing raw and adjusted R-squared. These 15 
models were designed to assess the influence of several variables known to have adverse 16 
prognostic effects in acute stroke (e.g., atrophy and stroke severity)(9) and whether their effects 17 
were attenuated/mediated in fully adjusted models. We determined the influence of adjustment 18 
variables by firstly modelling pairwise associations (unadjusted models) between BP 19 
variability and leukoaraiosis.  20 
21 
6 
 
Results 1 
Patient characteristics 2 
Full characteristics of the N=3035 patients, including treatment for hypertension prior to trial 3 
admission, stroke subtypes, atrophy and leukoaraiosis CT findings, are provided in supplement; 4 
18 patients did not have CT scans so did not contribute leukoaraiosis or atrophy scores in this 5 
analysis. Mean age was 77.3±12.2 years with median NIHSS 11 (IQR=11), and TACI 6 
(N=1306, 43%) was the most frequent stroke subtype. BP values by leukoaraiosis group, 7 
unadjusted for covariates, are provided in supplement. 8 
 9 
Association between leukoaraiosis and acute absolute BP 10 
The following are all adjusted analyses; beta coefficients and P-values are in Table 1. 11 
Systolic (155±24 mmHg to 146±23 mmHg) and diastolic (82±15 mmHg to 78±14 mmHg) BP 12 
generally fell with time from pre-randomization to 24 hours after start of treatment (P<0.005). 13 
Systolic BP was 3.58 (95% confidence interval, CI, ±2.5) mmHg lower and diastolic BP was 14 
3.80 (95% CI ±1.5) mmHg lower throughout the measurement period in patients with 15 
leukoaraiosis grade zero versus grade four. Systolic BP was higher (β=0.23, P<0.0001) and 16 
diastolic BP was lower (β=-0.14, P<0.0001) in older patients. 17 
 18 
Mean arterial pressure was lower in those with leukoaraiosis grade zero versus grade four, but 19 
not associated with age, while pulse pressure was higher in older people but not associated with 20 
leukoaraiosis (Table 1). 21 
 22 
Unadjusted associations between leukoaraiosis and acute BP variability 23 
Unadjusted pairwise associations between leukoaraiosis and BP variability (systolic, diastolic, 24 
pulse, mean) characterized by CV were not statistically significant (P>0.05). All other 25 
measures of BP variability (except successive variability in pulse pressure, P>0.05) were 26 
significantly associated with leukoaraiosis, where greater variability was associated with 27 
increased burden of leukoaraiosis, when not adjusting for covariates (P<0.05; see supplement).  28 
 29 
 30 
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Adjusted associations between leukoaraiosis and acute BP variability 1 
The following are all adjusted analyses; beta coefficients and P-values are in Table 2. 2 
In contrast to the unadjusted pairwise associations, leukoaraiosis was not associated with BP 3 
variability in the acute phase of ischaemic stroke, whether measured by CV (column 1 Table 4 
2), standard deviation (column 2 Table 2), average real variability (column 3 Table 2), or 5 
successive variability (column 4 Table 2) when adjusting for age, atrophy, stroke severity, 6 
subtype, and treatment groups. 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
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Discussion 1 
In this large study including 3017 patients, we found that leukoaraiosis was associated with 2 
high absolute BP, but not with BP variability, over the first 24 hours after ischaemic stroke 3 
when adjusting for relevant covariates. At first there did appear to be a positive association 4 
between leukoaraiosis and acute BP variability measured by standard deviation, average real 5 
variability, and successive variability, however these associations disappeared when adjusting 6 
for age and other relevant covariates. Therefore, while BP variability is associated with poor 7 
outcome in IST-3(1), it is not likely to explain the association between leukoaraiosis and poor 8 
outcome after acute stroke, that we also found in IST-3(9). Higher absolute BPs were 9 
associated with the presence of grade four leukoaraiosis versus grade zero; but patients with 10 
grade four leukoaraiosis did not have higher absolute BP compared to patients with 11 
leukoaraiosis grades one to three, after adjusting for age.  12 
 13 
Our finding that short-term BP variability in acute ischaemic stroke is not independently 14 
associated with leukoaraiosis is consistent with two previous studies (N total=68), including 15 
one of non-acute lacunar stroke patients (N=43)(10, 12). Additionally, the lack of association 16 
between leukoaraiosis and BP variability is consistent with the largest previous study we found 17 
(N=694), that was conducted in community-dwelling subjects(6). However, our finding 18 
contrasts with previous smaller studies (N=66; N=210; N=155) of community-dwelling older 19 
subjects that found an association between increased variability in short-term BP and 20 
leukoaraiosis(13, 22). Additionally, positive associations between leukoaraiosis and BP 21 
variability have been found in primary hypertensive (N=487)(23) and cardiovascular disease 22 
(N=39)(24) patients. This discord may be due to acute ischaemia masking associations between 23 
BP variability and leukoaraiosis, the physiology of patient groups versus community dwelling 24 
participants, continual monitoring versus intermittent BP measures, or that previous sample 25 
sizes were much smaller (generally N<250) than here. Independent studies of absolute BP and 26 
leukoaraiosis may have similar differences in their study design, however, these have still 27 
produced generally consistent associations between higher absolute BP and more 28 
leukoaraiosis; and the number of these studies far outweighs the number of studies into BP 29 
variability and leukoaraiosis(14). 30 
 31 
The strengths of our study include the large number of acute ischaemic stroke patients with BP 32 
9 
 
monitoring within the first 24 hours of stroke at fixed intervals according to standardised 1 
protocols; and recording of BP lowering treatment before, during the first 24 hours, and 2 
between two and seven days after trial enrolment. IST-3 settings and patients reflect a broad 3 
range of hospital environments charged with the care of ischaemic stroke. The number of 4 
participants studied here is over four times greater than the largest study of BP variability and 5 
leukoaraiosis that we found(6). Finally, we assessed a range of BP variability measures 6 
compared with previous studies that used only one measure(11, 12). 7 
 8 
Despite these strengths, our study has some limitations. As we used data from a randomized-9 
controlled trial, there is always a risk of confounding. For example, we were not able to control 10 
for some vascular risk factors such as cholesterol, which may have an influence on associations 11 
between BP and leukoaraiosis(14). MRI has greater sensitivity than CT for detecting 12 
leukoaraiosis but CT is much more widely used in acute stroke and detects established 13 
leukoaraiosis. We had limited information on BP prior to enrolment in the trial, beyond 14 
reported use of antihypertensive treatment, therefore do not know the duration of elevated BP 15 
prior to the trial. This means that we cannot ascertain whether those with higher BP and more 16 
leukoaraiosis had chronically high BP or only acutely high BP. Continuous monitoring of BP 17 
may identify subtle associations between BP variability and leukoaraiosis that we were not able 18 
to detect here. Other limitations related to BP measurements and the lack of random allocation 19 
to BP lowering treatment in IST-3 have previously been discussed at length(1). Our results may 20 
not apply to patients with haemorrhagic stroke as IST-3 only included ischaemic stroke. 21 
However, several completed or ongoing trials of BP lowering in haemorrhagic stroke also use 22 
similar scan assessments and therefore could assess leukoaraiosis and BP variability.  23 
 24 
Notwithstanding, we have shown that patients with leukoaraiosis have high BP but do not have 25 
increased BP variability immediately after ischaemic stroke. While additional work is required 26 
in this area, our results suggest that BP variability is not a potential mechanism to explain the 27 
association between leukoaraiosis and poor outcome after acute ischaemic stroke. 28 
 29 
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Table 1. Regression-based associations between absolute BP (dependent variable) and leukoaraiosis (independent variable) with relevant 1 
covariates 2 
  Diastolic BP Systolic BP Pulse Pressure Mean arterial pressure 
Parameter Level Beta  P-value Beta  P-value Beta  P-value Beta  P-value 
Time (from pre-rand to 24 hours)  -1.28  <0.0001* -2.32  <0.0001* -1.05  <0.0001* -1.63  <0.0001* 
Age  -0.14  <0.0001* 0.23  <0.0001* 0.38  <0.0001* -0.02  0.52 
Leukoaraiosis versus grade 4 0 -3.80  <0.0001* -3.58  0.0042* 0.21  0.85 -3.73  <0.0001* 
 1 -1.73  0.06 0.37  0.81 2.09  0.10 -1.03  0.29 
 2 -0.44  0.57 0.37  0.78 0.80  0.47 -0.18  0.83 
 3 -0.40  0.74 -0.07  0.97 0.31  0.86 -0.30  0.82 
No atrophy  0.09  0.89 0.41  0.69 0.33  0.69 0.20  0.77 
NIHSS  -0.06  0.13 -0.05  0.46 0.01  0.82 -0.06  0.19 
Stroke subtype versus LACI PACI -0.54  0.45 -0.55  0.68 0.04  0.97 -0.53  0.52 
 POCI -0.55  0.55 -0.05  0.98 0.53  0.69 -0.39  0.70 
 TACI -0.04  0.96 1.47  0.33 1.56  0.21 0.47  0.62 
Time to randomization (hours)  0.21  0.19 0.50  0.08 0.29  0.23 0.31  0.09 
Control versus rt-PA  0.62  0.14 0.63  0.37 0.01  0.99 0.63  0.17 
BP lowering prior to study  -1.35  0.0092* -0.92  0.29 0.39  0.57 -1.21  0.0339* 
BP lowering in 1st 24 hours  2.57  <0.0001* 3.83  <0.0001* 1.27  0.09 3.00  <0.0001* 
BP lowering 24hr-7days  1.04  0.07 5.24  <0.0001* 4.22  <0.0001* 2.44  <0.0001* 
Note: BP=blood pressure; SE=standard error; *P<0.05; NIHSS=National Institutes of Health Stroke Scale; LACI=lacunar infarcts; PACI=partial 3 
anterior circulation infarcts; POCI=posterior circulation infarcts, TACI=total anterior circulation infarcts; rt-PA=recombinant tissue-type 4 
plasminogen activator. 5 
Beta are not standardised. 6 
 7 
 8 
 9 
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Table 2. Regression-based associations between leukoaraiosis (dependent variable) and BP variability (independent variables) with relevant 1 
covariates 2 
  Coefficient of variance Standard deviation Average real variability Successive variability 
Parameter Level Beta  P-value Beta  P-value Beta  P-value Beta  P-value 
Diastolic BP  -1.71  0.09 0.02  0.38 0.01  0.55 0.00  0.94 
Systolic BP  -1.89  0.16 0.01  0.37 0.01  0.31 0.00  0.12 
Pulse pressure  0.41  0.30 -0.01  0.23 -0.01  0.20 0.00  0.14 
Mean arterial pressure  2.36  0.21 -0.02  0.38 -0.01  0.58 null  . 
Age  0.02  <0.0001* 0.02  <0.0001* 0.03  <0.0001* 0.03  <0.0001* 
NIHSS  0.00  0.63 0.00  0.70 0.00  0.38 0.00  0.40 
No atrophy  -0.79  <0.0001* -0.78  <0.0001* -0.76  <0.0001* -0.76  <0.0001* 
Stroke subtype versus LACI PACI  -0.13  0.09 -0.14  0.09 -0.18  0.0303* -0.18  0.0339* 
 POCI -0.02  0.82 -0.03  0.79 -0.08  0.48 -0.08  0.50 
 TACI -0.13  0.14 -0.14  0.13 -0.20  0.0347* -0.20  0.0398* 
Time to randomization (hours)  -0.02  0.21 -0.02  0.24 -0.01  0.75 -0.01  0.75 
Control versus rt-PA  0.03  0.56 0.03  0.54 0.05  0.29 0.05  0.27 
BP lowering prior to study  0.06  0.26 0.06  0.28 0.03  0.58 0.03  0.59 
BP lowering in 1st 24 hours  0.10  0.07 0.10  0.06 0.09  0.15 0.08  0.16 
BP lowering on days 2-7  -0.04  0.54 -0.04  0.52 0.00  0.96 0.00  0.97 
Note: Leukoaraiosis is the dependent variable in this table, all associations shown are with Leukoaraiosis. BP=blood pressure; SE=standard error; 3 
*P<0.05; NIHSS=National Institutes of Health Stroke Scale; LACI=lacunar infarcts; PACI=partial anterior circulation infarcts; POCI=posterior 4 
circulation infarcts, TACI=total anterior circulation infarcts; rt-PA=recombinant tissue-type plasminogen activator. 5 
Mean arterial pressure parameter Beta for successive variation was set to null because it is a linear combination of successive variation in diastolic 6 
(SV_DBP), systolic BP (SV_SBP), and pulse pressure (SV_PP), i.e., 0.66667 * SV_DBP + 0.33333 * SV_SBP - 0.22222 * SV_PP (see equations 7 
1 and 3). 8 
Beta are not standardised. 9 
 10 
